| Order number | Description | Quantity | Delivery time | CE |
|---|---|---|---|---|
| TB T1301 | TriniCLOT Fibrinogen Kit | kit | 10-15 days | x |
TriniCLOT Fibrinogen KitTriniCLOT Fibrinogen Kit is intended for quantitative determination of fibrinogen in plasma. Fibrinogen is the plasma protein precursor of fibrin, which when cross-linked, becomes the principal component of the fibrin clot. Thrombin cleaves fibrinogen to form a fibrin monomer. Fibrin monomers aggregate to form the insoluble fibrin polymers. Fibrinogen can be deficient in such conditions as congenital afibrinogenemia, hypofibrinogenemia and in some cases of dysfibrinogenemia. It can also be depressed in a number of disease states such as disseminated intravascular coagulation, systemic fibrinolysis, pancreatitis and severe hepatic dysfunction. Fibrinogen is an acute phase reactant protein whose concentration increases in response to many different physiological stimuli. It can be increased as a response to inflammatory states, with infections, during pregnancy and after trauma. It is elevated among smokers. High fibrinogen levels in plasma have been associated with prethrombotic states. Fibrinogen levels have also been positively correlated to development of atherosclerotic cardiovascular disease and with the occurrence of myocardial infarction and stroke. Because of the increased importance of the assessing fibrinogen levels, a reliable, sensitive procedure is necessary. Most methods for determining fibrinogen concentration rely on the assumption that thrombin will quantitatively convert fibrinogen to fibrin. Estimation of concentration based on the weight or protein content of the formed fibrin clot may be subject to large errors due to the presence of inhibitors which cause little or no clot to form. Plasmin can also produce significant lysis of the formed clot before the final fibrinogen determination can be completed. Alternate procedures based on ammonium sulfate precipitation have been described but do not correlate with thrombin clotting times when fibrinogen levels are below 100 mg/dl (1.0 g/L). The determination of biologic activity (i.e. clottability) is more useful in diagnosis than is the quantity of circulating fibrinogen. The method of Clauss8 measures the rate of fibrinogen to fibrin conversion in the presence of excess thrombin and has been shown to be rapid, sensitive and precise. The procedure described here is based on the Clauss method. When diluted plasma is clotted with excess thrombin, the fibrinogen level is inversely proportional to the clotting time, yielding a curvilinear relationship when plotted on log-log paper. A calibration curve prepared from a fibrinogen reference is used to determine the fibrinogen concentration in the test sample. |
Additional Documentation
|
Login